科技导报 >

2014 , Vol. 32 >Issue 24: 15 - 24

DOI: https://doi.org/10.3981/j.issn.1000-7857.2014.24.001

本刊专稿

埃博拉病毒病：流行病学、生态学、诊断、治疗及控制

  • 李昱 ,
  • 任翔 ,
  • 刘翟 ,
  • 程颖 ,
  • 高福 ,
  • 余宏杰
展开
  • 1. 中国疾病预防控制中心传染病预防控制处, 传染病监测预警中国疾病预防控制中心重点实验室, 北京102206;
    2. 中国科学院微生物研究所病原微生物与免疫学重点实验室, 北京100101;
    3. 中国疾病预防控制中心, 北京102206
李昱，研究实习员，研究方向为传染病流行病学、传播动力学和监测，电子信箱：liyu1@chinacdc.cn

收稿日期: 2014-08-20

  网络出版日期: 2014-08-27

收起

Ebola Virus Disease: Epidemiology, Ecology, Diagnosis, Treatment, and Control

  • LI Yu ,
  • REN Xiang ,
  • LIU Di ,
  • CHENG Ying ,
  • GAO George Fu ,
  • YU Hongjie
Expand
  • 1. Division of Infectious Disease, Key Laboratory of Surveillance and Early-warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China;
    2. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China;
    3. Chinese Center for Disease Control and Prevention, Beijing 102206, China

Received date: 2014-08-20

  Online published: 2014-08-27

Fold

摘要

埃博拉病毒（Ebolavirus）是埃博拉病毒病（Ebola Virus Disease, EVD）的病原体，1976 年首次在非洲发现，目前确认该病毒包括5 个种，其中苏丹型（Sudan ebolavirus）、扎伊尔型（Zaire ebolavirus）、塔伊森林型（Taï Forest ebolavirus）和本迪布焦型（Bundibugyo ebolavirus）均有感染人发病的记录；莱斯顿型（Reston ebolavirus）可致人隐性感染，并与多起猕猴暴发疫情有关，曾在菲律宾的猪中检出。人类埃博拉病毒病的病死率为25%~90%，疫情均发生在非洲，主要集中在10°N—10°S 的非洲地区，本次西非疫情是规模最大的暴发流行，截至2014 年8 月20 日已报告2615 例病例。该病是动物源性传染病，目前证据支持果蝠可能为病毒的自然储存宿主。该病在人群中主要通过接触传播，有症状的病人才具有传染性。未采取正确防护措施的医护人员、家庭护理人员及接触病人血液、体液，或接触病人血液、体液等污染的物品，或接触病例尸体的人是高风险感染人群。本病起病急，早期表现为发热、厌食、虚弱无力等非特异性症状，可通过检测病毒核酸、抗原、抗体等方法确诊。目前尚无批准上市的特效药和疫苗，以对症和支持治疗为主。预防控制策略主要包括早期发现病例、及时调查处置、追踪和密切观察接触者，以及有效的医院内和社区的感染控制。

关键词： 埃博拉病毒病; 埃博拉病毒; 流行病学

本文引用格式

李昱 , 任翔 , 刘翟 , 程颖 , 高福 , 余宏杰 . 埃博拉病毒病：流行病学、生态学、诊断、治疗及控制[J]. 科技导报, 2014 , 32(24) : 15 -24 . DOI: 10.3981/j.issn.1000-7857.2014.24.001

Abstract

Ebolavirus is the causative agent of Ebola Virus Disease (EVD) and was first found in 1976 in Africa. The genus of Ebolavirus includes 5 species, of which the 4 species, i.e., Sudan ebolavirus, Zaire ebolavirus, Taï Forest ebolavirus and Bundibugyo ebolavirus caused human cases of EVD in the history. The additional species, Reston ebolavirus, was associated with several outbreaks among monkeys and was once isolated from domestic pigs of Philippines. EVD has a fatality rate between 25% and 90%, with its outbreaks in humans limited to Africa and mainly happened in central Africa between 10°N and 10°S so far. The ongoing outbreak in West Africa has been the biggest one, with 2615 cases reported as of August 20, 2014. EVD is widely considered to be a zoonosis and its most likely natural reservoirs are fruit bats based on the current evidence. Ebolavirus can spread within human, mainly through contact of blood and secretions of patients presenting symptoms and the contaminated objects as well. So the health care staff, home care person and individuals with contact of corpse of EVD cases are the high risk population for infection. EVD has an abrupt onset of early symptoms such as fever, anorexia and weakness, which are nonspecific. But the disease can be diagnosed through testing RNA, antigen, or antibody. There have been no licensed drugs or vaccine in the market, while the treatment is still limited to treating the symptoms as they appear and supportive care. The current strategy for prevention and control includes early detection of cases, rapid investigation and response, tracing and close observation of high risk contact, and effective infection control in the health care facilities and the community.

Key words： Ebola virus disease; Ebolavirus; epidemiology

参考文献

[1] World Health Organization. Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation (Interim version 1.1) [M/OL].[2014-08-10]. http://www.who.int/csr/disease/ebola/manual_EVD/en.
[2] WorldHealthOrganization.WHOstatementonthemeetingoftheInternational Health Regulations Emergency Committee regarding the 2014 Ebola outbreak in West Africa [EB/OL]. (2014-08-08) [2014-08-10]. http:// www.who.int/mediacentre/news/statements/2014/polio-20140505/en.
[3] Centres for Disease Prevention and Control. Ebola hemorrhagic fever- 2014 Ebola outbreak in West Africa [EB/OL]. [2014-08-24]. http://www. cdc.gov/vhf/ebola/outbreaks/guinea/index.html.
[4] Cheng Y, Liu J, Li Y, et al. Ebloa viral disease: Update research of etiology, pathogenic mechanism, treatment and vaccine[J]. Chinese Science Bulletin, (under review).
[5] World Health Organization. Ebola haemorrhagic fever in Sudan, 1976 [J]. Bull World Health Organ, 1978, 56: 247-270.
[6] World Health Organization. Ebola haemorrhagic fever in Zaire, 1976 [J]. Bull World Health Organ, 1978, 56: 271-293.
[7] Cox N J, McCormick J B, Johnson K M, et al. Evidence for two subtypes of Ebola virus based on oligonucleotide mapping of RNA [J]. J Infect Dis, 1983, 147: 272-275.
[8] Jahrling P B, Geisbert T W, Johnson E D, et al. Preliminary report: Isolation of Ebola virus from monkeys imported to USA[J]. The Lancet, 1990, 335: 502-505.
[9] Le Guenno B, Formenty P, Wyers M, et al. Isolation and partial characterisation of a new strain of Ebola virus [J]. The Lancet, 1995, 345: 1271-1274.
[10] Wamala J F, Lukwago L, Malimbo M, et al. Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007—2008 [J]. Emerg Infect Dis, 2010, 16(7): 1087-1092.
[11] Emond R T, Evans B, Bowen E T, et al. A case of Ebola virus infection[J]. British Medical Journal. 1977, 2(6086): 541-544.
[12] Borisevich I V, Markin V A, Firsova I V, et al. Hemorrhagic (Marburg, Ebola, Lassa, and Bolivian) fevers: Epidemiology, clinical pictures, and treatment [J]. Voprosy Virusologii-Problems of Virology, 2006, 51(5): 8- 16.
[13] Akinfeyeva L A, Aksyonova O I, Vasilyevich I V, et al. A case of Ebola hemorrhagic fever[J]. Infektsionnye Bolezni, 2005, 3(1): 85-88.
[14] Barrette R W, Metwally S A, Rowland J M, et al. Discovery of swine as a host for the Reston ebolavirus [J]. Science, 2009, 325: 204-206.
[15] Jahrling P B, Geisbert T W, Johnson E D, et al. Preliminary report: Isolation of Ebola virus from monkeys imported to USA[J]. The Lancet, 1990, 335: 502-505.
[16] Hayes C G, Burans J P, Ksiazek T G. Outbreak of fatal illness among captive macaques in the Philippines caused by an Ebola-related filovirus[J]. The American Journal Tropical Medicine and Hygiene, 1992, 46: 664-671.
[17] World Health Organization. Viral haemorrhagic fever in imported monkeys[R]. Weekly Epidemiological Record, Ceneva: WHO, 1992, 67 (24): 183.
[18] Rollin P E, Williams J, Bressler D, et al. Isolated cases of Ebola (subtype Reston) virus among quarantined non-hman primates recently imported from the Philippines to the United States[J]. Journal of Infectious Diseases, 1999, 179 (Suppl 1): 108-114.
[19] Miranda M E, Ksiazek T G, Retuya T J, et al. Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996[J]. Journal of Infectious Diseases, 1999, 179 (Suppl 1): 115-119.
[20] Miranda M E, White M E, Dayrit M M, et al. Seroepidemiological study of filovirus related to Ebola in the Philippines [J]. The Lancet, 1991, 337: 425-426.
[21] Centers for Disease Control and Prevention. Update: Filovirus infection in animal handlers [J]. Morbidity Mortality Weekly Report, 1990, 39 (13): 221.
[22] World Health Organization. Ebola virus disease in Guinea—23 March 2014 [EB/OL]. [2014- 03- 25]. http://www.who.int/csr/don/2014_03_ 23_ebola/en.
[23] Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea- Preliminary Report[J]. N Engl J Med, [2014- 08-14] http://www.nejm.org/doi/full/10.1056/NEJMoa1404505.
[24] European Centre for Disease Prevention and Control. Outbreak of Ebola virus disease in West Africa [R/OL]. (2014-08-01)[2014-08-14]. http:// www.ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm. aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1141.
[25] Pourrut X, Délicat A, Rollin P E, et al. Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species [J]. J Infect Dis, 2007, 196 Suppl 2): 176-183.
[26] Towner J S, Amman B R, Sealy T K, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats [J]. PLoS Pathogens, 2009, 5.[2014-08-14] http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713404.
[27] Leroy E M, Epelboin A, Mondonge V, et al. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007[J]. Vector-Borne and Zoonotic Diseases, 2009, 9: 723-728.
[28] Bausch D G, Nichol S T, Muyembe- Tamfum J J, et al. Marburg haemorrhagic fever associated with multiple genetic lineages of virus [J]. N Engl J Med, 2006, 355: 909-919.
[29] Bausch D G, Borchert M, Grein T, et al. Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo[J]. Emerg Infect Dis, 2003, 9: 1531-1537.
[30] Leroy E M, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus[J]. Nature，2005, 438 (7068): 575-576.
[31] Swanepoel R, Leman P A, Burt F J, et al. Experimental inoculation of plants and animals with Ebola virus[J]. Emerg Infect Dis, 1996, 2(4): 321-325.
[32] Morvan J M, Deubel V, Gounon P, et al. Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic [J]. Microbes and Infection, 1999, 1: 1193-1201.
[33] Leroy E M, Rouquet P, Formenty P, et al. Multiple Ebola virus transmission events and rapid decline of central African wildlife [J]. Science, 2004, 303(5656): 387-390.
[34] Formenty P, Boesch C, Wyers M, et al. Ebola virus outbreak among wild chimpanzees living in a rain forest of Cote d'Ivoire [J]. J Infect Dis, 1999, 179(Suppl 1): 120-126.
[35] Bermejo M, Rodríguez-Teijeiro J D, Illera G, et al. Ebola outbreak killed 5000 gorillas[J]. Science, 2006, 314 (5805): 1564.
[36] Nkoghe D, Formenty P, Leroy E M, et al. Multiple Ebola virus haemorrhagic fever outbreaks in Gabon, from October 2001 to April 2002[J]. Bull Soc Pathol Exot. 2005, 98 (3): 224-229.
[37] Formenty P, Libama F, Epelboin A, et al. Outbreak of Ebola hemorrhagic fever in the Republic of the Congo, 2003: a new strategy[J]. Med Trop (Mars). 2003, 63(3): 291-295.
[38] Feldmann H, Jones S, Klenk H D, et al. Ebola virus: From discovery to vaccine [J]. Nature Reviews Immunology, 2003, 3(8): 677-685.
[39] Heinz F, Thomas W G. Ebola haemorrhagic fever [J]. The Lancet, 2011, 377: 849-862.
[40] Groseth A, Feldmann H, Strong J E. The ecology of Ebola virus [J]. Trends in Microbiology, 2007, 15(9): 408-416.
[41] Pan Y, Zhang W, Cui L, et al. Reston virus in domestic pigs in China [J]. Arch Virol, 2014, 159(5): 1129-1132.
[42] Georges A J, Leroy E M, Renaud A A, et al. Ebola hemorrhagic fever outbreaks in Gabon, 1994—1997: Epidemiologic and health control issues[J]. J Infect Dis, 1999, 179(Suppl 1): 65-75.
[43] Geisbert T W, Hensley L E, Larsen T, et al. Pathogenesis of Ebola haemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection [J]. Am J Pathol, 2003, 163(6): 2347-2370.
[44] Kuniholm M H. Bat exposure is a risk factor for Ebola virus infection[C]// Filoviruses: Recent advance and future challenges: An ICID Global Symposium, Winnipeg, Manitoba, Canada, 2006.
[45] Peters C J, LeDuc L W. Ebola: The virus and the disease [J]. J Infect Dis, 1999, 179 (Suppl 1): 1-288.
[46] Khan A S, Tshioko F K, Heymann D L, et al. The reemergence of Ebola haemorrhagic fever, Democratic Republic of the Congo, 1995 [J]. J Infect Dis, 1999, 179 (Suppl 1): 76-86.
[47] Ksiazek T G, West C P, Rollin P E, et al. ELISA for the detection of antibodies to Ebola virus [J]. J Infect Dis, 1999, 179 (Suppl 1): 192-198.
[48] Rodriguez L L, De Roo A, Guimard Y, et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995 [J]. J Infect Dis, 1999, 179 (Suppl 1): 170- 176.
[49] Zaki S R, Shieh W J, Greer P W, et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: Implications for diagnosis, spread, and surveillance of Ebola haemorrhagic fever [J]. J Infect Dis, 1999, 179(Suppl 1): 36-47.
[50] Jahrling P B, Geisbert T W, Jaax N K, et al. Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989— 1990 U.S. epizootic [J]. Arch Virol, 1996, 11 (Suppl 1): 115-134.
[51] Piercy T J, Smither S J, Steward J A, et al. The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol [J]. J Appl Microbiol. 2010, 109 (5): 1531-1539.
[52] Geisbert T W, Daddario-Dicaprio K M, Geisbert J B, et al. Vesicular stomatitis virus- based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses [J]. Vaccine, 2008, 26 (52): 6894-6900.
[53] Bertherat E, Renaut A, Nabias R, et al. Leptospirosis and ebola virus infection in five gold-panning villages in northeastern Gabon[J]. Am J Trop Med Hyg, 1999, 60(4): 610-615.
[54] Rowe A K, Bertolli J, Khan A S, et al. Clinical, virologic, and immunologic follow- up of convalescent Ebola haemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo [J]. J Infect Dis, 1999, 179 (Suppl 1): 28-35.
[55] Colebunders R, Borchert M. Ebola haemorrhagic fever—A review [J]. J Infect, 2000, 40(1): 16-20.
[56] Centres for Disease Control and Prevention. Interim guidance for monitoring and movement of persons with Ebola virus disease exposure[R/OL]. [2014- 08- 15]. http://www.cdc.gov/vhf/ebola/hcp/monitoringand- movement-of-persons-with-exposure.html.
[57] Centres for Disease Control and Prevention. Ebola hemorrhagic feversigns and symptoms [EB/OL]. [2014- 08- 15]. http://www.cdc.gov/vhf/ ebola/symptoms/index.html.
[58] Okware S I, Omaswa F G, Zaramba S, et al. An outbreak of Ebola in Uganda[J]. Tropical Medicine and International Health. 2002, 7(12): 1068-1075.
[59] Kortepeter M G, Bausch D G, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever [J]. J Infect Dis, 2011, 204 (Suppl 3): 810-816.
[60] Bwaka M A, Bonnet M J, Calain P. Ebola hemorrhagic fever in Kikwit, Democratic Republic of Congo: Clinical observations in 103 patients [J]. J Infect Dis, 1999, 179(Suppl 1): 1-7.
[61] Strong J E, Grolla A, Jahrling P B, et al. Filoviruses and arenaviruses[C]// Detrick B, Hamilton R G, Folds J D. Manual of molecular and clinical laboratory immunology. 7th ed. Herndo, Virginia: ASM Press, 2006: 774-790.
[62] US Food and Drug Administration. Emergency use authorizations-2014 Ebola virus emergency use authorization [EB/OL]. [2014-08-17]. http:// www.fda.gov/medicaldevices/safety/emergencysituations/ucm161496. htm.
[63] Centres for Disease Control and Prevention. Ebola hemorrhagic feverdiagnosis[ EB/OL].[2014-08-15].http://www.cdc.gov/vhf/ebola/diagnosis/ index.html.
[64] Fauci A S. Ebola—Underscoring the global disparities in health care resources[EB/OL]. [2014-08-17]. http://www.nejm.org/doi/full/10.1056/ NEJMp1409494.
[65] Centre for Infectious Disease Research and Ppolicy. Experimental Ebola drug may have helped 2 US patients [EB/OL]. [2014-08-11]. http://www.cidrap.umn.edu/news-perspective/2014/08/experimental-ebola- drug-may-have-helped-2-us-patients.
[66] Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola haemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee [J]. J Infect Dis, 1999, 179 (Suppl 1): 18-23.
[67] Feldmann H, Jones S M, Schnittler H J, et al. Therapy and prophylaxis of Ebola virus infections [J]. Curr Opin Investig Drugs, 2005, 6(8): 823-830
[68] Bray M, Paragas J. Experimental therapy of filovirus infections [J]. Antiviral Res, 2002, 54 (1): 1-17.
[69] Centres for Disease Prevention and Control. Ebola hemorrhagic fever-treatment [EB/OL]. [2014-08-16]. http://www.cdc.gov/vhf/ebola/ treatment/index.html.
[70] Huggins J W. Prospects for treatment of viral haemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug [J]. Rev Infect Dis, 1989, 11 (Suppl 4): 750-761.
[71] Ignatyev G, Steinkasserer A, Streltsova M, et al. Experimental study on the possibility of treatment of some haemorrhagic fevers [J]. J Biotechnol, 2000, 83(1/2): 67-76.
[72] MacNeil A, Farnon E C, Morgan O W, et al. Filovirus outbreak detection and surveillance: Lessons from Bundibugyo[J]. J Infect Dis, 2011, 204 (Suppl 3): 761-767.
[73] Borchert M, Mutyaba I, van Kerkhove M D, et al. Ebola haemorrhagic fever outbreak in Masindi District, Uganda: Outbreak description and lessons learned [J]. BMC Infect Dis, 2011, 11: 357.
[74] World Health Organization, Centres for Disease Control and Prevention. Infection Control for Viral Haemorrhagic Fevers [R/OL]. [2014-08-15]. http://www.cdc.gov/vhf/abroad/pdf/african-healthcare-setting-vhf.pdf.
[75] Dowell S F, Mukunu R, Ksiazek T G, et al. Transmission of Ebola haemorrhagic fever: A study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995 [J]. J Infect Dis, 1999, 179 (Suppl 1): 87-91.
[76] Lloyd E S, Zaki S R, Rollin P E, et al. Long-term disease surveillance in Bandundu region, Democratic Republic of the Congo: A model for early detection and prevention of Ebola haemorrhagic fever [J]. J Infect Dis, 1999, 179 (Suppl 1): 274-280.
Options
文章导航

/

〈 〉

联系我们

  • 地址：北京市海淀区学院南路86号科技导报社　邮编：100081
  • 电话：010-62138113　传真：010-62138113
  • E-mail：kjdbbjb@cast.org.cn

    • 访问统计

      总访问量
      今日访问
      在线人数
    科技导报官方微信公众号
    京ICP备14028469号-1　
    版权所有 © 《科技导报》编辑部